Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease

Acta Biochimica Polonica

Volumn 58, Issue 4, 2011, Pages 563-566

  Lebensztejn, Dariusz M ^a   Wierzbicka, Aldona ^b   Socha, Piotr ^b   Pronicki, Maciej ^b   Skiba, Elzbieta ^a   Werpachowska, Irena ^a   Kaczmarski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Children; Cytokeratin 18; Hyaluronic acid; Laminin; NAFLD; YKL 40

Indexed keywords

NUCLEOPOLYHEDROVIRUS;

EID: 84860449503     PISSN: 0001527X     EISSN: 1734154X     Source Type: Journal    
DOI: 10.18388/abp.2011_2225     Document Type: Article

References (25)

1. Afdhal NH (2004) Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem 50: 1299-1300
2. Carter-Kent C, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC et al (2009) Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 50: 1113-1120.
3. Civera M, Urios A, Garcia-Torres ML, Ortega J, Martinez-Valls J, Cassinello N et al. (2010) Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. Diabetes Metab Res Rev 26: 187-192.
4. Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, Hazen SL et al. (2008) Cytokeratin-18 fragments levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 6: 1249-1254.
5. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P (2009) The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20-years. Gut 58: 1538-1544.
6. Feldstein AE, Wieckowska A, Lopez AR, Liu Y-C, Zein NN, Mc-Cullough AJ (2009) Cytokeratin-18 fragments levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50: 1072-1078.
7. Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, deBruyne R, Dhawan A (2010) Serum levels of CK-18 and leptin are useful predictors of steatohepatitis and fibrosis in pediatric NAFLD. J Pediatr Gastroenterol Nutr 51: 500-506.
8. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA (1996) Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis of trauma of the knee joint. Br J Rheumatol 35: 553-559.
9. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
10. Lavine J, Shwimmer J (2004) Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 8: 549-558.
11. Lebensztejn DM, Kaczmarski M, Sobaniec-Lotowska M, Bauer M, Voelker M, Schuppan D (2004) Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B. Hepatology 39: 868-869.
12. Lebensztejn DM, Skiba E, Sobaniec-Lotowska M, Kaczmarski M (2007) Serum hyaluronan and laminin level in children with chronic hepatitis B during long term lamivudine treatment. Hepatogastroenterology 54: 834-838.
13. Lebensztejn DM, Sobaniec-Lotowska M, Bauer M, Kaczmarski M, Voelker M, Schuppan D (2005) Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B. Eur J Gastroenterol Hepatol 17: 843-848.
14. Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D et al (2009) The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 24: 564-568.
15. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, Mc-Cullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413-1419.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28: 412-419.
17. Nobili V, Alisi A, Torre G, De Vito R, Pietrobattista A, Morino G et al (2010) Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. Trans Res 156: 229-234.
18. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE (2006) Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 43: 413-427.
19. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S et al. (2004) Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 50: 1344-1355.
20. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128: 1898-1906.
21. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C (2006) Prevalence of fatty liver in children and adolescents. Pediatrics 118: 1388-1393.
22. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K (2005) Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 25: 779- 786.
23. Trivedi B, Cheeseman P, Mowat AP (1993) Serum hyaluronic acid in health infants and children and its value as a marker of progressive hepatobiliary disease starting in infancy. Clin Chim Acta 21: 29-39.
24. Valva P, De Matteo E, Galoppo M, Pedreira A, Giacove G, Lezama C et al. (2008) Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients. Human Pathol 39: 1816-1822.
25. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE (2006) In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44: 27-33.